SCHEMBL6737339

SCHEMBL6737339

CCOC(=O)c1ccc2nnn(COCC[Si](C)(C)C)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.45
NPC1 O15118 2/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 3/20 0.45
MAPK1 P28482 1/20 0.44
HCAR3 P49019 1/20 0.42
PDE2A O00408 3/20 0.42
PDE10A Q9Y233 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
SIRT2 Q8IXJ6 3/20 0.39
SIRT1 Q96EB6 2/20 0.39
ALDH1A1 P00352 3/20 0.38
PPARG P37231 1/20 0.38
NCOA2 Q15596 1/20 0.38
NCOA1 Q15788 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29699134 0.91 MAPT (0.54) RAB9ANPC1LMNAMAPTMAPK1
SCHEMBL24494650 0.91 MAPT (0.54) RAB9ANPC1LMNAMAPTMAPK1
SCHEMBL31377132 0.89 LMNA (0.44) RAB9ANPC1LMNAMAPTHCAR3
SCHEMBL29627173 0.78 RAB9A (0.41) RAB9ANPC1MAPTPDE2ACA12
SCHEMBL28753181 0.78 RAB9A (0.41) RAB9ANPC1MAPTPDE2ACA12
SCHEMBL31377182 0.76 NPC1 (0.35) RAB9ANPC1HCAR3
SCHEMBL20401617 0.76 RAB9A (0.35) RAB9ANPC1LMNAMAPTHCAR3
SCHEMBL2144445 0.76 RAB9A (0.33) RAB9ANPC1LMNAHCAR3L3MBTL1
SCHEMBL26645068 0.76 DGAT1 (0.42) RAB9ANPC1
SCHEMBL31132754 0.76 PDE2A (0.50) RAB9ANPC1LMNAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127507-A1 Imidazolidine compounds MILLENNIUM PHARMACEUTICALS, INC. (US) 2004-07-01 US disclosed
US-20040122026-A1 Imidazolidine compounds MILLENNIUM PHARMACEUTICALS, INC. 2004-06-24 US disclosed
US-20030225288-A1 Imidazolidine compounds MILLENNIUM PHARMACEUTICALS, INC. 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127507-A1 Imidazolidine compounds IRAK1, IRAK4, IRAK2 RAB9A 1483/4885NPC1 401/4885LMNA 4169/4885
US-20030225288-A1 Imidazolidine compounds IRAK1, IRAK4, IRAK2 RAB9A 1483/4885NPC1 401/4885LMNA 4169/4885
US-20040122026-A1 Imidazolidine compounds IRAK1, IRAK4, IRAK2 RAB9A 1483/4885NPC1 401/4885LMNA 4169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.